Abstract: Breast cancer is the most common cancer among women worldwide. Discomfort and fatigue are usually arisen from anticancer therapy such as surgery, radiotherapy, chemotherapy, hormonal therapy, or combination therapy, because of the suppressed immunological functions. Yunzhi (Coriolus versicolor) can modulate various immunological functions in vitro, in vivo, and in human clinical trials. Danshen (Salvia miltiorrhiza) has been shown to benefit the circulatory system by its vasodilating and anti-dementia activity. The purpose of this clinical trial was to evaluate the immunomodulatory effects of Yunzhi-Danshen capsules in post-treatment breast cancer patients. Eighty-two patients with breast cancer were recruited to take Yunzhi [50 mg/kg body weight, 100% polysaccharopeptide (PSP)] and Danshen (20 mg/kg body weight) capsules every day for a total of 6 months. EDTA blood samples were collected every 2 months for the investigation of immunological functions. Flow cytometry was used to assess the percentages and absolute counts of human lymphocyte subsets in whole blood. Plasma level of soluble interleukin-2 receptor (sIL-2R) was measured by enzymelinked immunosorbent assay (ELISA). Results showed that the absolute counts of T-helper lymphocytes (CD4+), the ratio of T-helper (CD4+)/T suppressor and cytotoxic lymphocytes (CD8+), and the percentage and the absolute counts of B-lymphocytes were significantly elevated in patients with breast cancer after taking Yunzhi-Danshen capsules, while plasma sIL-2R concentration was significantly decreased (all p < 0.05). Therefore, the regular oral consumption of Yunzhi-Danshen capsules could be beneficial for promoting immunological function in post-treatment of breast cancer patients.
Introduction
Breast cancer is the most common cancer for women worldwide (Ursin et al., 1994) . The prevalence of breast cancer increases with age (Ursin et al., 1994) . The medical approaches for treatment of breast cancer are surgery, radiotherapy, chemotherapy, hormonal therapy, or combination therapy. Fatigue is one of the common side effects of cancer treatment. Studies have found that up to 99% of breast cancer patients experience some level of fatigue during the course of radiation therapy and/or chemotherapy, and more than 60% of fatigue were rated as moderate to severe (Blesch et al., 1991; Irvine et al., 1994) . Other studies have also shown that the intensity and duration of fatigue experienced by breast cancer patients undergoing treatment are significantly greater than that experienced by healthy controls (Irvine et al., 1998; Hann et al., 1998) . Indeed, fatigue was considered to be the most distressing side effect of treatment in a group of breast cancer patients receiving adjuvant chemotherapy (Knobf, 1986) . Discomfort and fatigue are common issues from the cancer treatment due to the suppressed immunological functions (Knobf, 1986) .
Polysaccharopeptide (PSP, a kind of polyglycopeptide) is one of the polysaccharides isolated from the COV-1 strain of Yunzhi (Coriolus versicolor) . Pharmacological studies indicated that PSP had in vitro antitumor activities, while having little inhibitory effect on normal cell lines (Hsieh et al., 2001; Yang et al., 1993) . In animal experiments, PSP could inhibit the growth of tumors, and the histopathological examination did not show any toxicity of PSP at a therapeutically effective dose in vivo (Yang et al., 1993) . PSP was also found to up-regulate the immune response in cancer radiotherapy (Mao et al., 2001) and restore the immunosuppression in animals (Qian et al., 1997) . In phase II and III of double-blind trials in China, the use of PSP could boost immune cell proliferation, alleviate chemotherapy symptoms, and enhance tumor infiltration by dendritic cells and cytotoxic T-lymphocytes (CTL) (Kidd, 2000) . In a recent clinical trial, PSP treatment slowed down deterioration of patients with advanced non-small cell lung cancer by increasing blood leucocyte and neutrophil counts, as well as serum IgG and IgM concentrations (Tsang et al., 2003) . Therefore, immunomodulatory activities of Yunzhi may have potential benefits on survival and quality of life, and is compatible with chemotherapy and radiation therapy of cancer (Wong et al., 1994) .
Danshen (Salvia miltiorrhiza) has been shown to have a beneficial effect on the circulatory system with vasodilating activity (Kamata et al., 1993) , and anti-dementia effect (Nomura et al., 1997) . Moreover, recent studies have demonstrated that Danshen exhibits chemopreventive effect against aflatoxin B1-induced hepatocarcinogenesis, inhibit cell growth and induce apoptosis in human hepatoma HepG2 cells (Liu et al., 2000, 2001a and . Moreover, one of the active ingredients in Danshen, Tanshinone IIA, is a newly confirmed antioxidant that inhibited the association of lipid peroxidation products with DNA (Cao et al., 1996) . Therefore, it is believed that Danshen can be beneficial for the protection of immune system and cardiovascular system by scavenging free radicals. Since antioxidants in diet supplements may have potential to indirectly improve the immune function in human beings (de la Fuente et al., 1998) 
Patients and Methods

Breast Cancer Patients
Female patients (n = 82) were recruited between June and October 2002 from the referrals of the Prince of Wales Hospital, Kwong Wah Hospital, Breast Surgery Associates and public inquiries in Hong Kong. The inclusion criteria comprised of: (1) age between 30 to 65; (2) stage I to III breast cancer based on TNM Classification and the American Joint Committee on Cancer (AJCC) Stage Groupings designated by AJCC (Woodward et al., 2003) ; (3) completion of anticancer treatment within the last 3 years; (4) absence of cancer metastases; (5) normal hematopoietic function: white blood cells ≥ 4000/mm 3 and platelet count ≥ 1,000,000/mm 3 ; (6) normal liver function: serum alanine transaminase ≤ 58 U/L and bilirubin ≤ 20 μM; and (7) normal renal function: serum creatinine ≤ 120 μM. The exclusion criteria included: (1) stage IV breast cancer; (2) serious concomitant diseases and non-malignant systemic diseases (including clotting disorders); (3) psychiatric or addictive disorders; (4) pregnancy, breastfeeding, or planning to be pregnant within 1 year; (5) taking concomitant medication besides tamoxifen therapy; (6) taking active agents of other traditional chinese medicine (TCM); and (7) history of significant drug hypersensitivity.
In this multi-center and self-controlled study, 82 patients received Yunzhi-Danshen combination capsules for 6 successive months. They were advised to avoid taking any other forms of TCM during this period. Immunological markers and quality of life were assessed at each visit every 2 months. Due to ethical consideration documented in the International Conference on Harmonization (ICH)-Good Clinical Practices (GCP) guideline, placebo would not be necessary if a clinical trial involves life-threatening disease such as cancer and AIDS. Therefore, the placebo-controlled design was not employed in this study. The protocol was approved by the Clinical Research Ethics Committee of the Chinese University of Hong Kong, and written informed consent was obtained from the participants.
Study Medication
Yunzhi-Danshen combination capsules were supplied by Winsor Health Products Ltd and were manufactured conforming to the Good Manufacturing Practice (GMP) standard. The Yunzhi-Danshen capsules were prepared using hot water extraction and lyophilization. The active drug, Yunzhi (50 mg/kg body weight, 100% PSP)-Danshen (20 mg/kg body weight) capsules, were taken orally daily. The ratio of the weight of Yunzhi and Danshen in the capsule was 7:3. The drug period was 6 months from the day of informed consent and baseline screening.
Blood Samples
Venous peripheral EDTA blood (6 ml) was collected from each subject before and every 2 months [time points of month (M) 0, 2, 4 and 6] after taking Yunzhi-Danshen capsules. EDTA blood (100 μl) was processed immediately for flow cytometric analysis of the percentages and absolute counts of human lymphocyte subsets. The remaining blood sample was used to obtain plasma, which was preserved at −70°C for subsequent assay.
Flow Cytometric Analysis of CD4+, CD8+, Natural Killer (NK) and B-Lymphocytes
The MultiTEST IMK Kit with TruCOUNT tubes (Becton Dickinson Corp, CA, USA) and the lyse/no-wash method were used for the assessment of the ratio and absolute counts of CD4+, CD8+, NK and B-lymphocytes in whole blood samples using a four-color FASCalibur flow cytometer (Becton-Dickinson) (Wong et al., 2003) .
Cytokine Receptor Assay
The concentration of plasma soluble IL-2 receptor (sIL-2R) was measured by solid phase enzyme-linked immunosorbent assay (ELISA) using the reagent kit of Diaclone Research Corp., Besancon, France.
Statistical Analysis
ANOVA (Univariate) for repeat measurements was used for the evaluation of changes in the percentages and absolute counts of CD4+/CD8+/NK/B-cells and soluble IL-2R concentration. All analyses were performed using the Statistical Package for Social Sciences (SPSS) for windows, Version 10.0 (SPSS Inc, IL, USA). The results were presented with mean ± SD, because the data were in Gaussian distribution. A probability p < 0.05 was considered as significantly different.
Results
Dropout of Subjects During Study
Within the 6-month study period, there were a total of three dropout cases, two of them withdrew from the trial during the second treatment period (after M2), and one withdrew during the last treatment period (after M4). They discontinued the study due to different reasons such as failure of blood taking and fear of infection. However, no serious adverse effect was reported in the whole study period of all participants. The demographical information of the remaining 79 recruited breast cancer patients are listed in Table 1 . Among them, 56 patients treated with tamoxifen therapy. Of the patients without tamoxifen therapy (n = 23), 11 patients completed the anticancer treatment for less than 10 months, 12 patients completed the anticancer treatment for more than 10 months. YUNZHI 
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Flow Cytometric Analysis of Percentage, Absolute Counts and Ratio of CD4+/CD8+/NK/B Lymphocytes
As shown in Table 2 and Fig. 1a , the percentage of CD8+ cells, comprising T-suppressor (Ts) and cytotoxic T-lymphocytes (CTL), in patients without tamoxifen therapy (n = 23) was significantly decreased after taking Yunzhi-Danshen capsules for 4 and 6 months. The percentage of T-helper (Th) lymphocytes (CD4+) to total lymphocytes was significantly elevated in the patients after taking the capsules for 6 months (Table 2 and Fig. 1b) . Consequently, the ratio of Th (CD4+)/Ts and CTL (CD8+) lymphocytes was significantly elevated in the patients after taking the capsules for 4 and 6 months ( Table 2 and Fig. 1c) . Besides, the percentage (Table 2 and Fig. 1d ) and the absolute counts (Table 2 and Fig. 1e ) of B-lymphocytes (CD19+) were significantly increased in patients after taking the capsules for 2, 4 and 6 months, and 4 and 6 months, respectively (all p < 0.05).
For patients with tamoxifen therapy (n = 56), the percentage (Table 2 and Fig. 2a ) and the absolute counts (Table 2 and Fig. 2b ) of Ts and CTL cells (CD8+) were significantly decreased after taking the capsules for 2, 4 and 6 months, and 6 months respectively. The ratio of Th (CD4+)/Ts and CTL (CD8+) T-cells was elevated in patients after taking the capsules for 6 months (Table 2 and Fig. 2c) . Besides, the percentage (Table 2 and Fig. 2d ) and absolute counts (Table 2 and Fig. 2e) of B-lymphocytes (CD19+) were significantly elevated for 2, 4 and 6 months, and 4 and 6 months, respectively (all p < 0.05). However, there was no significant difference in NK cells (p > 0.05). Table 3 and Figs. 3a and 3b show the results from patients who completed the anticancer treatment for less than 10 months without tamoxifen therapy (n = 11). The absolute counts of Th (CD4+) and the ratio of Th (CD4+)/Ts and CTL (CD8+) were significantly elevated after taking Yunzhi-Danshen capsules for 4 and 6 months. In addition, the percentage (Table 3 and Fig. 3c ) and absolute counts (Table 3 and Fig. 3d) of B-lymphocytes (CD19+) were significantly elevated after taking capsules for 2, 4 and 6 months, while the percentage of Ts and CTL cells (CD8+) was significantly decreased after taking capsules for 4 and 6 months (Table 3 and Fig. 3e ) (all p < 0.05). However, there was no significant difference in NK cells.
For patients with anti-cancer treatment for more than 10 months without tamoxifen therapy (n = 12), the percentage of Th (CD4+) ( Table 3 and Fig. 4a ) and the ratio of Th (CD4+)/CTL (CD8+) ( Table 3 and Fig. 4b ) lymphocytes were significantly elevated after taking Yunzhi-Danshen capsules for 6 months (all p < 0.05).
ELISA of Plasma Soluble IL-2 Receptor (sIL-2R)
Plasma sIL-2R concentration of breast cancer patients, which was higher than normal healthy subjects (data not shown), was significantly decreased after taking Yunzhi-Danshen capsules for 4 and 6 months (Figs. 5a and 5b).
Discussion
Yunzhi polysaccharopeptide (PSP) has documented immunomodulatory and antitumor activities from in vitro, in vivo studies, and human clinical trials (Fisher and Yang, 2002; Chow et al., 2003; Dong et al., 1997; Wang et al., 1996) . Recent studies have indicated that PSP can improve blood leukocyte and neutrophil counts, serum IgG and IgM concentrations, and slow down the deterioration of advanced non-small cell lung cancer (NSCLC) patients (Tsang et al., 2003) . In addition, PSP can also counteract the suppressive effect of cyclophosphamide on white blood cell count, interleukin-2 production, and delayed-type hypersensitivity reaction (Ng, 1998) . Administration of PSP to esophageal cancer, gastric cancer, or lung cancer patients with radiotherapy or chemotherapy can alleviate symptoms and prevent the decline of immune status (Ng, 1998) .
Most of these findings suggested that the anticancer effects might come from the activation of various host-mediated immune responses (Wasser, 2002; Shibata et al., 2002; Saji et al., 1999) . In the present clinical trial of Yunzhi-Danshen capsules in post-treatment breast cancer patients, we found that the ratio of Th/(Ts and CTL) lymphocytes and the percentage and the absolute counts of B-lymphocytes were significantly elevated in the breast cancer patients with or without tamoxifen therapy after taking Yunzhi-Danshen capsules. In view of the enhancement of Th/(Ts and CTL) ratio, absolute counts and percentage of B-cells, Yunzhi-Danshen capsules could be beneficial for immunomodulatory function by enhancing cell-mediated immunity and humoral immunity in post-treatment breast cancer patients in whom the immune system was suppressed by radiotherapy and/or chemotherapy. As shown in Table 3 and Fig. 3a , the absolute counts of Th was significantly elevated after taking Yunzhi-Danshen capsules for 4 months in breast cancer patients who completed anticancer treatment for less than 10 months without tamoxifen YUNZHI-DANSHEN IN BREAST CANCER PATIENTS therapy. These results suggest regular oral consumption of Yunzhi-Danshen capsules could be beneficial for promoting cell-mediated immunological function in post-treatment breast cancer patients, particularly in those with completion of anticancer treatment for less than 10 months without tamoxifen therapy replacement.
In our present study, plasma sIL-2R concentration in patients was significantly decreased after taking Yunzhi-Danshen capsules for 4 and 6 months (Fig. 5a) . Lissoni et al. (1990) reported that elevated serum sIL-2R concentration was associated with various neoplastic diseases such as breast cancer, colon cancer, acute lymphoblastic leukemia, (a) (b)
